Biology of sex differences · 2026
Sex differences in the clinical outcomes of chronic hepatitis B infection among paediatric patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ouyang Wenxian, Yao Zhenzhen, Gu Yingping, Lai Xin, Peng Songxu
Аннотация
BACKGROUND: The impacts of sex on treatment response in paediatric patients with chronic hepatitis B virus (HBV) infection remains incompletely understood. We aimed to analyse sex differences in antiviral treatment response in children with HBV infection.
METHODS: We performed a retrospective cohort study on 236 treatment-naive children with chronic HBV infection at the Liver Disease Centre of Hunan Children's Hospital. The Cox proportional hazard regression was used to estimated treatment outcome differences between males and females.
RESULTS: Of the 236 subjects, the median age at treatment initiation was 4 (2,7) years, and 155 (65.68%) were male. After the median follow-up (IQR) of 27 (18, 43) months, the crude cumulative incidence of HBsAg loss, HBeAg clearance and HBV DNA undetectability in patients were 48.73%, 61.02% and 89.36%, respectively. Kaplan-Meier curve showed that female patients were more likely to achieving HBsAg loss compared to male patients (58.02% vs. 43.87%, Plog-rank=0.001). After adjustment for other covariates, female sex was significantly associated with the higher possibility of HBsAg loss (female vs. male: Adjusted HR: 2.03, 95% CI: 1.35-3.06) in children with chronic HBV infection. Furthermore, the landmark analysis revealed that the relationship between sex and HBsAg loss became more pronounced beyond the first year (female vs. male: adjusted HR (95%CI): 2.18(1.29-3.69)).
CONCLUSION: Children with chronic HBV infection receiving antiviral treatment are frequently observed to achieve functional cure. Sex plays an important role in treatment response among paediatric patients, with female patients exhibiting a higher likelihood of achieving HBsAg loss, particularly after one- year of follow-up.
METHODS: We performed a retrospective cohort study on 236 treatment-naive children with chronic HBV infection at the Liver Disease Centre of Hunan Children's Hospital. The Cox proportional hazard regression was used to estimated treatment outcome differences between males and females.
RESULTS: Of the 236 subjects, the median age at treatment initiation was 4 (2,7) years, and 155 (65.68%) were male. After the median follow-up (IQR) of 27 (18, 43) months, the crude cumulative incidence of HBsAg loss, HBeAg clearance and HBV DNA undetectability in patients were 48.73%, 61.02% and 89.36%, respectively. Kaplan-Meier curve showed that female patients were more likely to achieving HBsAg loss compared to male patients (58.02% vs. 43.87%, Plog-rank=0.001). After adjustment for other covariates, female sex was significantly associated with the higher possibility of HBsAg loss (female vs. male: Adjusted HR: 2.03, 95% CI: 1.35-3.06) in children with chronic HBV infection. Furthermore, the landmark analysis revealed that the relationship between sex and HBsAg loss became more pronounced beyond the first year (female vs. male: adjusted HR (95%CI): 2.18(1.29-3.69)).
CONCLUSION: Children with chronic HBV infection receiving antiviral treatment are frequently observed to achieve functional cure. Sex plays an important role in treatment response among paediatric patients, with female patients exhibiting a higher likelihood of achieving HBsAg loss, particularly after one- year of follow-up.